#1 Clinical Trials Search in Europe

VANDETANIB

Clinical trials investigating VANDETANIB are studying its role in people with RET-mutant medullary thyroid cancer. These trials look at how well it works compared with other treatments and measure outcomes such as progression-free survival. The main focus is on patients with progressive, advanced disease who have not had prior kinase inhibitor treatment.

Table of Contents

Clinical trial overview

The available trial is a Phase 3 study in RET-mutant medullary thyroid cancer.[1] It compares selpercatinib with cabozantinib or VANDETANIB in patients with progressive, advanced disease.[1]

The study is interventional, which means people in the trial receive a treatment so researchers can compare results between groups.[1] The trial is authorised and includes 273 participants.[1]

Who can join the study

This trial is for patients with progressive, advanced, kinase inhibitor naïve, RET-mutant medullary thyroid cancer.[1] “Kinase inhibitor naïve” means the patient has not had this type of cancer medicine before.[1]

The study population is therefore a specific group of thyroid cancer patients with a RET gene change and disease that is already advanced or getting worse.[1]

What the trial is measuring

The main outcome is progression-free survival (PFS) by BICR.[1] PFS means the time patients live without their cancer getting worse.[1]

BICR means blinded independent central review, so independent experts review the results without knowing which treatment each patient received.[1] This helps make the comparison between treatments more objective.[1]

Study design and phase

The study title shows that VANDETANIB is part of a comparison against selpercatinib and cabozantinib.[1] This type of design helps researchers see which treatment may work better in this cancer group.[1]

Because it is a Phase 3 trial, it is a later-stage study meant to test treatment benefit in a larger group of patients.[1]

Trial status and size

The trial status is Authorised.[1] The planned enrollment is 273 patients.[1]

Only one trial record was provided, so this article focuses on that study and its main goal: comparing treatment outcomes in RET-mutant medullary thyroid cancer.[1]

Trial ID Phase Condition studied Status Enrollment
2023-506782-56-00 Phase 3 RET-Mutant Medullary Thyroid Cancer Authorised 273

FAQ

  • What is being studied in VANDETANIB clinical trials? The trial is studying VANDETANIB as a treatment option for RET-mutant medullary thyroid cancer. It is being compared with other drugs to see which treatment helps patients stay free from disease progression longer.
  • Who can take part in the trial? The study is for patients with progressive, advanced, RET-mutant medullary thyroid cancer. It also focuses on people who have not previously received a kinase inhibitor, which is a type of cancer medicine.
  • What phase is the VANDETANIB trial? The trial is in Phase 3. This means it is a later-stage study that compares treatments in a larger group of patients.
  • What condition is the trial about? The trial is about RET-mutant medullary thyroid cancer. This is a type of thyroid cancer with a RET gene change.
  • What result is the trial mainly measuring? The main result is progression-free survival, or PFS. This means the study checks how long patients live without their cancer getting worse, and it is assessed by BICR, which means an independent review of scans and results.

Ongoing Clinical Trials on VANDETANIB

Unfortunately, we did not find any clinical trials matching the selected criteria. Try changing the filter settings or broadening the search criteria to see more available research participation opportunities.

Glossary

  • RET-mutant: A cancer with a change in the RET gene. This gene change can help doctors identify a specific group of patients for treatment studies.
  • Medullary thyroid cancer (MTC): A less common type of thyroid cancer that starts in special cells of the thyroid gland.
  • Progressive disease: Cancer that is growing or getting worse over time.
  • Advanced disease: Cancer that has spread or is not limited to one small area.
  • Kinase inhibitor: A type of cancer treatment that blocks signals used by cancer cells to grow. In this trial, patients had not used one before.
  • Phase 3: A later stage of clinical research that compares treatments in a larger group of patients.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives without the cancer getting worse.
  • BICR: Blinded independent central review. This means scans or results are checked by independent experts who do not know which treatment the patient received.
  • Interventional study: A study where participants receive a treatment or other intervention so researchers can measure its effects.

References

  1. https://clinicaltrials.gov/study/2023-506782-56-00